ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

J90 NurExone Biologic Inc

0,438
-0,008 (-1,79%)
26 Jul 2024 - Geschlossen
Echtzeitdaten
Name Symbol Markt Aktientyp
NurExone Biologic Inc J90 Tradegate Ordinary Share
  Änderung Änderung % Aktuell Zeit
-0,008 -1,79% 0,438 23:50:01
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,452 0,416 0,48 0,438 0,446
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.7.202422:14GLOBEPromising Preliminary Results in Optic Nerve Recovery Study..
05.7.202414:43GLOBEUpdates from NurExone: Growth Conference Presentation and..
28.6.202422:04GLOBENurExone’s ExoPTEN Being Studied as Glaucoma Treatment for..
21.6.202422:04GLOBEOn Path to First-in-Human Study, NurExone Engages Prominent..
11.6.202414:44GLOBENurExone Announces Expansion of ExoPTEN Patent Coverage with..
04.6.202422:40GLOBENurExone Announces Voting Results from 2024 Annual Meeting..
29.5.202414:35GLOBENurExone Reports First Quarter 2024 Financial Results and..
17.5.202422:04GLOBENurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive..
25.4.202414:35GLOBENurExone Biologic Inc. Announces Strategic Expansion to US..
19.4.202422:04GLOBENurExone Presenting on Revolutionary Spinal Cord Injury..
02.4.202414:31GLOBENurExone Reports Fourth Quarter and Year Ended December 31,..
27.3.202422:05GLOBEGross Proceeds Close of $4M CAD Generated for NurExone From..
22.3.202422:04GLOBEIn Preparation for Expected Human Clinical Trials, NurExone..
15.3.202421:05GLOBENurExone's Strategic Update: Submission of OTCQB Listing..
08.3.202422:05GLOBENurExone establishing State-of-the-Art Research and..
01.3.202422:04GLOBENurExone Presenting Novel Regulatory Pathways for Exosomes..
20.2.202422:05GLOBENurExone’s Intellectual Property Portfolio Expands
14.2.202422:20GLOBENurExone Launches Licensing Efforts for ExoTherapy Platform
02.2.202422:05GLOBENurexone Biologic Initiates European Orphan Drug Designation..
17.1.202414:34GLOBENurExone and Inteligex Kick Off Chronic Spinal Cord Injury..
05.1.202414:30GLOBENurExone Announces Closing of a Private Placement for Gross..
29.11.202314:30GLOBENurExone Biologic Extends Spinal Cord Injury Therapy..
24.11.202314:30GLOBENurExone Reports Third Quarter 2023 Financial Results and..
30.10.202314:20GLOBENurExone Biologic Receives FDA Orphan-Drug Designation,..
19.10.202314:30GLOBEAppointment of Professor Teo Forcht Dagi to Scientific..
11.10.202314:30GLOBENurExone Secures Eureka Grant for Collaborative..
05.10.202314:30GLOBENurExone Biologic to Present Exosome-Based Therapy for..
28.9.202314:30GLOBENurExone Appoints Dr. Reuter Investor Relations in Europe
13.9.202314:30GLOBENurExone Moves Forward Towards Human Clinical Trials,..
06.9.202314:30GLOBENurExone Announces Closing of Second Tranche of Private..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock